PrimaryBid SA was delighted to support MedinCell (Euronext: MEDCL) during its latest capital raise. The company, a commercial-stage pharmaceutical technology company developing a portfolio of long-acting injectable products in various therapeutic areas, successfully raised €25.1 million through an offering to French and international investors via a Private Placement and to retail investors via PrimaryBid.
Christophe Douat, CEO of MedinCell said: "We thank both our existing and new shareholders for their support and trust. We were also pleased to offer retail investors the opportunity to take part in the offering. The team is engaged and looking forward to pursuing the development of our portfolio, of which all candidate products are based on the same technology as UZEDYTM, our first product just approved by the FDA."
This French deal was only available to investors in France. Investing in securities involves risk.
Read more about the deal here.